IQVIA Holdings Inc. $IQV Shares Sold by Steward Partners Investment Advisory LLC

Key Points

• Steward Partners Investment Advisory LLC reduced its stake in IQVIA Holdings Inc. by 7.3%, owning 62,525 shares worth approximately $11 million after selling nearly 5,000 shares.
• Insider trading activity saw Keriann Cherofsky and Eric Sherbet each sell significant portions of their stocks, with Cherofsky reducing her position by 15.87% and Sherbet by 17.59%.
• IQVIA reported earnings of $2.81 per share in its latest quarter, exceeding analyst expectations, and its revenue rose to $4.02 billion, a 5.3% increase compared to the previous year.

Steward Partners Investment Advisory LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,525 shares of the medical research company's stock after selling 4,948 shares during the quarter. Steward Partners Investment Advisory LLC's holdings in IQVIA were worth $11,023,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new stake in IQVIA during the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd increased its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 3.0%

Shares of NYSE:IQV traded up $5.5970 during trading on Friday, hitting $190.9870. The company's stock had a trading volume of 1,619,418 shares, compared to its average volume of 1,441,272. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The stock's 50-day moving average price is $173.70 and its two-hundred day moving average price is $168.51. The company has a market capitalization of $32.47 billion, a PE ratio of 27.64, a PEG ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of several analyst reports. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial upped their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Barclays upped their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, UBS Group upped their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.